FHTX — Foghorn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1822462 ·
Last close
$2.00
Market Cap
$118.77M
52W High
$7.61
52W Low
$1.79
ADV30
1,026,135
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 16,072,000 | — | -8,805,000 | -7,191,000 | 203,393,000 | 68,080,000 | 284,434,000 |
| Mar 2026 | 3,267,000 | — | -21,573,000 | -19,875,000 | 222,167,000 | 87,663,000 | 298,575,000 |
| Dec 2025 | 9,247,000 | — | -19,596,000 | -21,664,000 | 198,103,000 | 80,876,000 | 306,603,000 |
| Sep 2025 | 8,153,000 | — | -18,501,000 | -15,849,000 | 204,962,000 | 89,334,000 | 294,620,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-84,241,000
Investing CF
$28,119,000
Financing CF
$50,380,000
CapEx
$-529,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.92
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-659,533,000
Inventory
—
Receivables
—
ST Investments
$99,502,000
EBIT TTM
$-68,475,000
Pretax Income TTM
$-64,579,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,739,000
EBITDA
$-66,353,000
Free Cash Flow
$-51,954,876
Enterprise Value
$138,003,088
Total Cash
$167,582,000
Total Debt
$43,102,000
Shares Out
59,385,315
Trailing EPS
$-0.99
Book Value
$-1.38
ROE
—
ROA
-19.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 30,909,000 | -82,107,000 | -74,283,000 | 198,103,000 | 306,603,000 | -108,500,000 | -86,099,000 |
| Dec 2024 | 22,602,000 | -100,285,000 | -86,620,000 | 283,982,000 | 329,510,000 | -45,528,000 | -100,406,000 |
| Dec 2023 | 34,155,000 | -107,906,000 | -98,426,000 | 285,916,000 | 363,106,000 | -77,190,000 | -118,106,000 |
| Dec 2022 | 19,228,000 | -117,137,000 | -108,882,000 | 404,883,000 | 404,771,000 | 112,000 | 193,612,000 |
TTM Snapshot
Revenues TTM
$28,224,000
NetIncome TTM
$-75,324,000
OpCashFlow TTM
—
Assets (Latest)
$222,167,000
Forward EPS
$-1.09
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.00 · call volume: 5 · put volume: 94
Expected Move to 2026-11-20:
±$0.72
(36.25%) —
implied range
$1.27 –
$2.73
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INO | INOVIO PHARMACEUTICALS, INC. | $118.91M | $1.15 | — |
| COYA | Coya Therapeutics, Inc. | $116.12M | $4.95 | — |
| GNLX | GENELUX Corp | $115.83M | $2.56 | — |
| VTVT | vTv Therapeutics Inc. | $123.28M | $31.18 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $123.39M | $2.85 | — |
News headlines (Yahoo Finance, 1h cache)
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
2026-10-02 18:12 · Yahoo
Sector Update: Healthcare Stocks Fall Late Afternoon
2026-10-01 19:57 · Yahoo
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
2026-10-01 19:51 · Yahoo
Top Midday Decliners
2026-10-01 18:44 · Yahoo
Lilly, Foghorn part ways; Wave’s FDA-approved plans
2026-10-01 16:04 · Yahoo
Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review
2026-10-01 14:06 · Yahoo
FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?
2026-10-01 13:23 · Yahoo
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
2026-10-01 11:00 · Yahoo
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
2026-08-26 13:55 · Yahoo
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy
2026-08-14 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.